某院120例AIDS患者不同HAART方案的药物不良反应分析Analysis of Adverse Reactions of Different HAART Regimens in 120 AIDS Patients in a Hospital
李伟煊,林昭平,雷露雯,莫迪威
LI Weixuan,LIN Zhaoping,LEI Luwen,MO Diwei
摘要(Abstract)：
目的回顾性分析某院艾滋病(AIDS)患者高效抗逆转录病毒治疗(HAART)过程中药物不良反应(ADR)发生的特点,为临床合理用药提供参考。方法将2014~2015年120例已确诊AIDS并接受HAART治疗的患者随机分为两组,分别为A组:拉米夫定+替诺福韦+依非韦伦(3TC+TDF+EFV);B组:齐多拉米双夫定+依非韦伦(AZT/3TC+EFV),根据Karch和Lasagna评定法对治疗过程中出现的ADR评定,并对ADR的类型、出现的时间及转归进行回顾性分析。结果 AIDS患者接受HAART治疗的总ADR发生率为80.8%,多发生在用药1年后,主要是血脂升高、肝肾功能异常、血液系统异常及高血糖。A组ADR发生率是86.7%,发生率最高为肾功能异常(53.3%);B组ADR发生率75%,发生率最高为血脂升高(43.3%)。结论 AIDS患者HAART方案ADR发生率高,需注意监测和对症处理,不同HAART方案ADR发生率及类型有差异,需要根据患者情况制定用药方案。
OBJECTIVE To analyze the features of adverse drug reactions( ADR) in patients with AIDS during HAART treatment,and provided reference for clinical rational drug used. METHODS 120 patients with HAART admitted to a hospital from2014 to 2015 were randomly divided into two groups,group A was lamivudine + tenofovir + efavirenz( 3TC+TDF+EFV),and group B was( Zidovudine and Lamivudine Tablets) + efavirenz( AZT/3TC + EFV). Using the Karch and Lasagna assessment methods to assessment the adverse reactions occurred or not. And the type of adverse reactions,the emergence of time and outcome were retrospectively analyzed. RESULTS Totally,the rate of ADR was 80.8%,and almost the adverse reactions occurred in the drug using after 1 year,such as hypercholesterolemia,liver and reral funtions,abnormality abnormal hematologic disorder and hyperglycaemia.The rate of adverse reactions in group A was 86.7%,renal disorder was the highest( 53.3%). And the rate of adverse reactions in group B was 75%,hematologic disorder was the highest( 43. 3%). CONCLUSION The patient with HAART have higher drug adverse reactions,need monitoring and treatment. And the types of adverse reactions and incidence rates exit some differences,individual treatment should be carried out on the patients.
关键词(KeyWords)：
艾滋病;高效抗逆转录病毒治疗;不良反应
AIDS;HAART;adverse reaction
基金项目(Foundation):
作者(Author):
李伟煊,林昭平,雷露雯,莫迪威
LI Weixuan,LIN Zhaoping,LEI Luwen,MO Diwei
参考文献(References)：
- [1]刘升,杜红,覃鸿发,等.不同抗病毒方案治疗艾滋病的临床疗效及不良反应分析[J].内科,2016,11(2):255-256.
- [2]中华医学会感染病学分会艾滋病学组.艾滋病诊疗指南第三版(2015版)[J].中华临床感染病杂志,2015,8(5):385-394.
- [3]《国家免费艾滋病抗病毒药物治疗手册》编写组.国家免费艾滋病抗病毒药物治疗手册[M].第3版.北京:人民卫生出版社,2012.
- [4]李俊.临床药理学[M].北京:人民卫生出版社,2013,138-150.
- [5]中华人民共和国卫生部.药品不良反应报告和监测管理办法[Z].2011.
- [6]方承松,何丽春,蒙志好.艾滋病患者抗逆转录病毒治疗药物不良反应的药学监护[J].中国医院药学杂志,2013,33(22):1888-1890.
- [7]戴国瑞,种雪静,肖江,等.成人HIV/AIDS病人HAART前血小板减少的发生率及相关因素分析[J].中国艾滋病性病,2016,22(11):860-863.
- [8]段兴钧,章银娣,杨宏,等.含TDF的HAART方案对抗逆转录病毒药物初治成年HIV感染患者肾功能的影响研究[J].中华疾病控制杂志,2015,19(12):1211-1214,1218.
- [9]WHO Guidelines Approved by the Guidelines Review Committee.Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection:Recommendations for a Public Health Approach.Geneva:World Health Organization;2013 Jun.
- [10]替诺福韦中文说明书[Z].2013年版.Aspen Port Elizabeth(Pty)Ltd.
- [11]齐多拉米双夫定片中文说明书[Z].2015年版.安徽贝克生物制药有限公司.
- [12]拉米夫定中文说明书[Z].2016年版.中孚药业股份有限公司.
- [13]依非韦伦中文说明书[Z].2014年版.浙江华海药业股份有限公司.
- [14]Lochet P,Peyrière H,LotthéA,et al.Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz[J].HIV Medicine,2003,4(1):62-66.
- [15]隆靖,殷琦敏,魏春波,等.HAART后高血脂症艾滋病患者生存质量调查及其影响因素分析[J].中国皮肤性病学杂志,2016,30(12):1252-1256.
- [16]陈淑怡,程伟彬,徐慧芳,等.广州市HIV感染者/AIDS病人社会支持与生活质量典型相关分析[J].广东药学院学报,2016,32(1):111-114.
- [17]吕日英,李国坚.高效抗逆转录病毒疗法在艾滋病治疗中的应用进展[J].中国临床新医学,2015,8(9):888-889.
- [18]Rachlis A R.Zidovudine(Retrovir)update[J].CMAJ,1990,143(11):1177-1185.
- [19]王家瑜,梅琼.59例拉米夫定药物不良反应分析[J].中国现代药物应用,2008,2(1):69-70.
- [20]李钰,严宇斌,黄琳.艾滋病抗病毒治疗药物不良反应与护理措施[J].护理实践与研究,2015,12(6):38-39.
- [21]姚娜,汪春付,赵升魁,等.西安市HIV/AIDS病人HAART依从性相关研究[J].中国艾滋病性病,2015,21(3):184-188.